MedTrace Logo

A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients

NCT02672540 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-05-23

No results posted yet for this study

Summary

Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis who are admitted to the hospital for treatment.

Conditions

  • Anemia, Sickle Cell

Interventions

DRUG

SANGUINATE 320 mg/kg

Two-hour infusion of SANGUINATE on Day 1 and Day 2

DRUG

Normal Saline

Two-hour infusion of Normal Saline and Day 1 and Day 2

Sponsors & Collaborators

  • Prolong Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Hemant Misra, PhD · Prolong Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Colombia
  • Dominican Republic
  • Honduras
  • Panama

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02672540 on ClinicalTrials.gov